Printer Friendly

United States : AbbVie Announces Phase 3 Study of VENCLEXTA/VENCLYXTO (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint.

AbbVie, a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study of VENCLEXTA/VENCLYXTO (venetoclax) in combination with Rituxan (rituximab) compared with bendamustine in combination with Rituxan in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).

Investigator-assessed results showed that patients with R/R CLL achieved significantly prolonged median progression-free survival (PFS) with VENCLEXTA/VENCLYXTO in combination with Rituxan median PFS, not reached , compared with bendamustine in combination with Rituxan median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.110.25; P

[c] 2017 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Article Type:Clinical report
Date:Dec 15, 2017
Previous Article:United States : IMBRUVICA (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host...
Next Article:Germany : RDM reduces costs and improves quality and productivity on BM 3 after rebuild project with Voith.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters